Why is Bharat Immunolog falling/rising?

As of 19-Sep, Bharat Immunological & Biological Corporation Ltd is currently priced at 22.01, reflecting a slight increase of 0.09 or 0.41%. The stock has shown a trend reversal by gaining after two consecutive days of decline. However, it is trading below all its moving averages, indicating a bearish trend. The stock's performance over the past week is relatively in line with the sector, but it has underperformed significantly over longer periods, with a year-to-date decline of 7.48% and a one-year drop of 21.78%. Key negative factors contributing to the stock's recent movement include weak long-term fundamentals, as the company has not declared results in the last six months, and a concerning debt-to-EBITDA ratio. Additionally, net sales have plummeted by 87.03% in the latest reporting period, further exacerbating investor concerns.
In the broader market context, the stock's short-term performance has lagged behind the benchmark, with a 1-week return of only 0.05% compared to the Sensex's gain of 0.88%. This consistent underperformance against the benchmark over the last three years highlights the stock's struggles to attract investor confidence. The falling investor participation, evidenced by a 35.41% drop in delivery volume, suggests a lack of interest in the stock, which is compounded by its high debt levels and poor growth metrics. Overall, while there is a minor uptick in the stock price, the underlying fundamentals and market sentiment indicate a challenging environment for Bharat Immunological & Biological Corporation Ltd.